Absence seizures associated with efavirenz initiation

Pediatric Infectious Disease Journal

Volumn 30, Issue 11, 2011, Pages 1001-1003

  Strehlau, Renate ^a   Martens, Leigh ^a   Coovadia, Ashraf ^a   Dandara, Collet ^b   Norman, Jennifer ^b   Maisel, Julia ^a   Kuhn, Louise ^c,d   Abrams, Elaine J ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d Columbia University ^*  (United States)

Author keywords

absence seizures; efavirenz; new onset

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE;

ARTICLE; CASE REPORT; CHILD; COMMUNICABLE DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERINATAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SEIZURE;

EID: 80055001114     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318223b680     Document Type: Article

References (24)

1. Teglas JP, Quartier P, Treluyer JM, et al. Tolerance of efavirenz in children. AIDS. 2001;15:241-243. (Pubitemid 32142300)
2. Hirt D, Urien S, Olivier M, et al. Are recommended dose of efavirenz optimal in young West African HIV infected children? Antimicrob Agents Chemother. 2009;53:4407-4413.
3. Rotger M, Colombo S, Furrer H, et al. Swiss HIV Cohort Study. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5. (Pubitemid 43205520)
4. National Department of Health. Guidelines for the Management of HIV in Children. 2nd ed. South Africa: National Department of Health; 2010.
5. World Health Organization. Annex E: Prescribing information and weight based dosing of available ARV formulations for infants and children. World Health Organization. 2010;P29.
6. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics. 2009;19:300-309.
7. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300. (Pubitemid 36734384)
8. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Parmacogenetics. 2001;11:399-415. (Pubitemid 32656581)
9. Gounden V, van Niekerk C, Snyman T, et al. Presence of the CYP2B6 516G+T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther. 2010;7:32.
10. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy efavirenz. Pharmacogenet Genomics. 2005;15:861-879.
11. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr. 2007;45:280-285. (Pubitemid 47012374)
12. Hoody DW, Fletcher CV. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis. 2003;14:286-294. (Pubitemid 38139833)
13. Ren Y, Nuttall JC, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr. 2007;45:133-136. (Pubitemid 46869804)
14. Gazzard BG. Efavirenz in the management of HIV infection. Int J Clin Pract. 1999;53:60-64. (Pubitemid 29073801)
15. FDA drug information sheet. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2005/020972s026,021360s013lbl.pdf.
16. McComsey G, Bhumbra N, Ma JF, et al. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. 2003;111:e275-e281.
17. Puthanakit T, Tanpaiboon P, Aurpibul L, et al. Plasma efavirenz concentrations and the association with CYP2B6-516G+T polymorphism in HIV infected Thai children. Antivir Ther. 2009;14:315-320.
18. Moyle G. Efavirenz: practicalities, considerations and new issues. Int J Clin Pract. 1999;(suppl 103):29-34.
19. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75. (Pubitemid 32055781)
20. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73:20-30. (Pubitemid 36158483)
21. Clifford DB, Evans S, Yang Y, et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10:343-355.
22. Wintergerst U, Hoffmann F, Jansson A, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother. 2008;61:1336-1339. (Pubitemid 351753604)
23. Viljoen M, Gous H, Kruger HS, et al. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS Res Hum Retroviruses. 2010;26:613-619.
24. Lowenhaupt EA, Matson K, Qureishi B, et al. Psychosis in a 12-year-old HIV positive girl with an increased serum concentration of efavirenz. Clin Infect Dis. 2007;45:e128-e130. (Pubitemid 351411927)